Daridorexant
Brand names: Quviviq · Active ingredient: Daridorexant
In short: QUVIVIQ is indicated for the treatment of adult patients with insomnia, characterized by difficulties with sleep onset and/or sleep maintenance .
What is Daridorexant used for?
QUVIVIQ is indicated for the treatment of adult patients with insomnia, characterized by difficulties with sleep onset and/or sleep maintenance .
Daridorexant dosage
The recommended dosage range is 25 mg to 50 mg of QUVIVIQ taken orally no more than once per night within 30 minutes of going to bed (with at least 7 hours remaining prior to planned awakening).
Time to sleep onset may be delayed if taken with or soon after a meal .
Co-administration with Strong CYP3A4 Inhibitors
Avoid concomitant use of QUVIVIQ with strong inhibitors of CYP3A4 .
Co-administration with Moderate CYP3A4 Inhibitors
The recommended dosage of QUVIVIQ is 25 mg no more than once per night when used with moderate inhibitors of CYP3A4 .
Co-administration with Strong or Moderate CYP3A4 Inducers
Avoid concomitant use of QUVIVIQ with strong or moderate CYP3A4 inducers .
The maximum recommended dosage in patients with moderate hepatic impairment (Child-Pugh score 7–9) is 25 mg of QUVIVIQ no more than once per night .
QUVIVIQ is not recommended in patients with severe hepatic impairment (Child-Pugh score ≥ 10) .
How to take Daridorexant — instructions & advice from the label
Advise the patient to read the FDA-approved patient labeling (Medication Guide).
Administration Instructions
Advise patients to take QUVIVIQ only in the evening within 30 minutes before going to bed and only if they can stay in bed for a full night (at least 7 hours) before being active again .
Advise patients that the effect of QUVIVIQ may be delayed if taken with or soon after a meal .
CNS-Depressant Effects and Daytime Impairment
Advise patients that QUVIVIQ can impair daytime wakefulness even when used as prescribed. The risk of daytime impairment is increased if QUVIVIQ is taken with less than a full night of sleep remaining or if a higher than recommended dose is taken. If QUVIVIQ is taken in these circumstances, caution patients against driving and other activities requiring complete mental alertness. Advise patients that increased drowsiness may increase the risk of falls in some patients .
Worsening of Depression/Suicidal Ideation
Tell patients to report any worsening of depression or suicidal thoughts immediately . …
Warnings & precautions
Do not take this medicine if: QUVIVIQ is contraindicated:
in patients with narcolepsy.
in patients with a history of hypersensitivity to daridorexant or any components of QUVIVIQ. Angioedema with pharyngeal involvement has been reported .
QUVIVIQ is a central nervous system (CNS) depressant that can impair daytime wakefulness even when used as prescribed. CNS-depressant effects may persist in some patients for up to several days after discontinuing QUVIVIQ. Prescribers should advise patients about the potential for next-day somnolence.
Driving ability was impaired in some subjects taking QUVIVIQ 50 mg . The risk of daytime impairment is increased if QUVIVIQ is taken with less than a full night of sleep remaining or if a higher than recommended dose is taken . If QUVIVIQ is taken in these circumstances, caution patients against driving and other activities requiring complete mental alertness.
Co-administration with other CNS depressants (e.g., benzodiazepines, opioids, tricyclic antidepressants, alcohol) increases the risk of CNS depression, which can cause daytime impairment. Dosage adjustments of QUVIVIQ and of concomitant CNS depressants may be necessary when administered together because of potentially additive effects. The use of QUVIVIQ with other drugs to treat insomnia is not recommended. Advise patients not to consume alcohol in combination with QUVIVIQ because co-administration of QUVIVIQ with alcohol resulted in additive effects on psychomotor performance .
Because QUVIVIQ can cause drowsiness, patients, particularly the elderly, are at a higher risk of falls.
Patients with psychiatric disorders, including insomnia, are at increased risk of suicide. In primarily depressed patients treated with hypnotics, worsening of depression and suicidal thoughts and actions (including completed suicides) have been reported. …
Daridorexant side effects
The following are discussed in detail in other sections of the labeling:
CNS-Depressant Effects and Daytime Impairment
Worsening of Depression/Suicidal Ideation
Sleep Paralysis, Hypnagogic/Hypnopompic Hallucinations, and Cataplexy-like Symptoms
Complex Sleep Behaviors
Patients with Compromised Respiratory Function
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in clinical trials of a drug cannot be directly compared to rates in clinical trials of another drug and may not reflect the rates observed in practice.
The safety of QUVIVIQ was evaluated in three placebo-controlled clinical studies (two 3-month studies of identical design [Study 1 and Study 2], and a 9-month extension study [Study 3]). Study 1 evaluated 50 mg and 25 mg doses of QUVIVIQ, while Study 2 evaluated a 25 mg dose and a 10 mg dose of QUVIVIQ. The 10 mg dose is not an approved dose. A total of 1232 patients (including approximately 40% elderly patients [≥ 65 years old]), received QUVIVIQ 50 mg (N = 308); 25 mg (N = 618); or 10 mg (an unapproved dose) (N = 306). A total of 576 patients were treated with QUVIVIQ for at least 6 months and 331 for at least 12 months.
Most Common Adverse Reactions
The most common reported adverse reaction (in at least 5% of patients and greater than placebo) during double-blind treatment in Study 1 was headache. …
Drug interactions
Table 2 describes clinically significant drug interactions where the concomitant use of other drugs affects QUVIVIQ.
Strong or Moderate CYP3A4 Inhibitors
Clinical Implications: | Concomitant use with a strong or moderate CYP3A4 inhibitor increases exposure to daridorexant , which may increase the risk of QUVIVIQ adverse reactions.
Prevention or Management: | The recommended dose of QUVIVIQ is 25 mg when used with a moderate CYP3A4 inhibitor . Concomitant use of QUVIVIQ with a strong inhibitor of CYP3A4 is not recommended .
Strong and Moderate CYP3A4 Inducers
Clinical Implications: | Concomitant use with a strong or moderate CYP3A4 inducer decreases exposure to daridorexant , which may reduce the efficacy of QUVIVIQ.
Prevention or Management: | Concomitant use of QUVIVIQ with a strong or moderate inducer of CYP3A4 is not recommended .
Alcohol and Other CNS Depressants
Clinical Implications: | Concomitant use of alcohol or other CNS depressants with QUVIVIQ may lead to additive impairment of psychomotor performance and risk of CNS depression .
Prevention or Management: | Avoid alcohol consumption with QUVIVIQ .Use with caution in patients receiving CNS depressants. Consider dose adjustment of QUVIVIQ and/or the CNS depressant(s) if used concomitantly . …
About this medicine
QUVIVIQ contains daridorexant, an orexin receptor antagonist, present as daridorexant hydrochloride salt. The chemical name of daridorexant hydrochloride is (S)-(2-(5-chloro-4-methyl-1H-benzo[d]imidazol-2-yl)-2-methylpyrrolidin-1-yl)(5-methoxy-2-(2H-1,2,3-triazol-2-yl)phenyl)methanone hydrochloride. The molecular formula is C23H23N6O2Cl * HCl. The molecular weight is 487.38 g/mol.
The structural formula is:
Daridorexant hydrochloride is a white to light yellowish powder that is very slightly soluble in water.
QUVIVIQ tablets are intended for oral administration. Each film-coated tablet contains daridorexant 25 mg or 50 mg, equivalent to 27 mg or 54 mg of daridorexant hydrochloride, respectively. The inactive ingredients are croscarmellose sodium, magnesium stearate, mannitol, microcrystalline cellulose, povidone, and silicon dioxide.
In addition, the film coating contains the following inactive ingredients: glycerin, hypromellose, iron oxide black, iron oxide red, microcrystalline cellulose, talc, titanium dioxide, and, in the 50 mg tablet only, iron oxide yellow. …
Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID 3a2d1503-b816-40c9-9fac-7e03c5a3bcef. Read the full official label on DailyMed.
Related medicines
Tirzepatide Buspirone Venlafaxine Zolpidem Citalopram Lorazepam Temazepam Melatonin